Top Articles

Volume 114, Number 5- PROGRESS IN HEMATOLOGY –

Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells (by Hiroshi Fujiwara)

Next-generation CAR T cells to overcome current drawbacks (by Stefan Lundh, et al.)

Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine (by Xiuli Wang, et al.)

Engineering the next generation of CAR-NK immunotherapies (by Alexander Biederstädt and Katayoun Rezvani)

Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors (by Tatsuki Ueda and Shin Kaneko)

Volume 113, Number 5- PROGRESS IN HEMATOLOGY –

Evolution of CML treatment (by Shinya Kimura) 

Current status and novel strategy of CML (by Kiyomi Morita and Koji Sasaki)

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia (by Hyewon Lee, et al.)

Treatment-free remission and immunity in chronic myeloid leukemia (by Hiroshi Ureshino)

New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism  (by Kazuhito Naka)

Volume 113, Number 1- PROGRESS IN HEMATOLOGY –

 Diversity of disseminated intravascular coagulaton and selection of appropriate treatments (by Hidesaku Asakura)

Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations (by Shinya Yamada and Hidesaku Asakura)

Recent advances in the research and management of sepsis-associated DIC (by Toshiaki Iba, et al.)

Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies (by Takayuki Ikezoe)

COVID-19-associated coagulopathy and disseminated intravascular coagulation (by Hidesaku Asakura and Haruhiko Ogawa)

Volume 111, Number 5- PROGRESS IN HEMATOLOGY –

Guest editorial: B1 cells: their ontogeny and malignant counterpart (by Naoyuki Katayama)

The ontogeny of murine B-1a cells (by Momoko Yoshimoto)

Ontogeny of human B1 cells (by Yuki Kageyama  and Naoyuki Katayama)

Pathophysiology of chronic lymphocytic leukemia and human B1 cell development (by Yoshikane Kikushige)

Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? (by Junji Suzumiya and Jun Takizawa)

Volume 111, Number 4- PROGRESS IN HEMATOLOGY –

Introduction by the Guest Editor: Recent advances in biology and treatment of multiple myeloma (by Hirokazu Tanaka)

Molecular basis of clonal evolution in multiple myeloma (by Yusuke Furukawa and Jiro Kikuchi)

Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost (by Kenshi Suzuki) 

Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan (by Hiroyuki Takamatsu)

Chimeric antigen receptor T-cell therapy for multiple myeloma (by Naoki Hosen)

Volume 111, Number 2- PROGRESS IN HEMATOLOGY -

Progress in elucidation of molecular pathophysiology and its application in therapeutic decision-making for myeloproliferative neoplasms (by Katsuto Takenaka)

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions (by Ruochen Jia and Robert Kralovics)

Mutational profiling in myelofibrosis: implications for management (by Prithviraj Bose and Srdan Verstovsek)

The role of calreticulin mutations in myeloproliferative neoplasms (by Marito Araki and Norio Komatsu)

The role of driver mutations in myeloproliferative neoplasms: insights from mouse models (by Kotaro Shide)

Volume 111, Number 1- PROGRESS IN HEMATOLOGY -

Current progress and future direction in the treatment for hemophilia (by Midori Shima)

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity (by Takehisa Kitazawa and Midori Shima)

Advances in gene therapy for hemophilia: basis, current status, and future perspectives (by Tsukasa Ohmori)

Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia (by Pratima Chowdary)

Volume 110, Number 2- PROGRESS IN HEMATOLOGY -

Epigenetic abnormalities and therapies for hematological malignancies (by Toshio Kitamura)

New insights into the biology of acute myeloid leukemia with mutated NPM1 (by Lorenzo Brunetti, et al.)

Clinical update on hypomethylating agents (by Matthieu Duchmann and Raphael Itzykson)

Deregulated Polycomb functions in myeloproliferative neoplasms (by Goro Sashida, et al.)

Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms (by Shuhei Asada and Toshio Kitamura)

Volume 110, Number 1- PROGRESS IN HEMATOLOGY -

Guest Editorial: Are “alternative” stem cell sources still alternative in the new era? (by Junya Kana)
Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation (by Koji Kawamura)
HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide (by Junichi Sugita)
Single cord blood transplantation in Japan; expanding the possibilities of CBT (by Hisashi Yamamoto)
Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells (by Ko K. Maung and Mitchell E. Horwitz)

Volume 109, Number 1- PROGRESS IN HEMATOLOGY -

Molecular pathogenesis of leukemia and leukemic stem cells (LSCs) (by Masahiro Kizaki)
Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia (by Tze King Tan, et al.)
Metabolism as master of hematopoietic stem cell fate (by Kyoko Ito, et al.)
Targeting transcription factors in acute myeloid leukemia (by Hisashi Takei and Susumu S. Kobayashi)
What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells (by Nathalia Azevedo Portilho, et al.)